Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 5/20 | 0.42 |
| ▸ | FPR2 | P25090 | 3/20 | 0.42 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL919163 | 0.91 | SCN9A (0.47) | SCN9AFPR2CARM1PRMT6LIPG | |
| SCHEMBL919294 | 0.86 | SLC1A3 (0.44) | SCN9AFPR2CARM1PRMT6MAOB | |
| SCHEMBL918991 | 0.83 | MAPK14 (0.50) | CYP3A4MAPK14MMP1MMP2MMP13 | |
| SCHEMBL920257 | 0.83 | FAAH (0.47) | SCN9AFPR2CARM1PRMT6MAP2K1 | |
| SCHEMBL919807 | 0.82 | CYP2C19 (0.47) | CARM1PRMT6CYP3A4MAPK14HPGD | |
| SCHEMBL920846 | 0.81 | MAPK14 (0.47) | SCN9ACYP3A4MAPK14MMP1MMP2 | |
| SCHEMBL919066 | 0.81 | PTGER4 (0.43) | SCN9ACARM1PRMT6MAP2K1 | |
| SCHEMBL919907 | 0.81 | PTGER4 (0.43) | SCN9AFPR2CARM1PRMT6MAOB | |
| SCHEMBL919395 | 0.79 | SCN9A (0.46) | SCN9AFPR2CARM1PRMT6CYP3A4 | |
| SCHEMBL3064569 | 0.79 | MAOB (0.58) | SCN9AMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303568-A1 | Substituted 2-Aminoacetamides and the Use Thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2013-11-14 | — | — | US | claimed |
| US-8426431-B2 | Substituted 2-aminoacetamides and the use thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2013-04-23 | — | — | US | claimed |
| EP-2201945-B1 | Use of substituted 2-aminoacetamides for treating or ameliorating anxiety | PURDUE NEUROSCIENCE COMPANY (US) | 2013-03-06 | — | — | EP | claimed |
| EP-2201944-B1 | Use of substituted 2-aminoacetamides for treating, preventing or ameliorating manic depression | PURDUE NEUROSCIENCE COMPANY (US) | 2012-05-23 | — | — | EP | claimed |
| EP-1032377-B1 | SUBSTITUTED 2-AMINOACETAMIDES AND THE USE THEREOF | PURDUE NEUROSCIENCE COMPANY (US) | 2010-11-17 | — | — | EP | claimed |
| EP-2201945-A2 | Substituted 2-Aminoacetamides and the Use Thereof | Purdue Neuroscience Company (US) | 2010-06-30 | — | — | EP | claimed |
| EP-2201944-A2 | Substituted 2-Aminoacetamides and the Use Thereof | Purdue Neuroscience Company (US) | 2010-06-30 | — | — | EP | claimed |
| EP-1032377-A4 | SUBSTITUTED 2-AMINOACETAMIDES AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2006-06-14 | — | — | EP | claimed |
| US-20030130295-A1 | Substituted 2-aminoacetamides and the use thereof | EURO-CELTIQUE S.A. | 2003-07-10 | — | — | US | claimed |
| US-6479484-B1 | SUBSTITUTED 2-AMINOACETAMIDES AND THE DISCOVERY THAT THESE COMPOUNDS ACT AS BLOCKERS OF SODIUM CHANNELS; PAIN RELIEVERS, TREATMENT OF ARRYTHMIA, LOCAL ANESTHETICS | EURO-CELTIQUE S.A. (LU) | 2002-11-12 | — | — | US | claimed |
| US-20020016464-A1 | Substituted 2-aminoacetamides and the use thereof | EURO-CELTIQUE S.A. | 2002-02-07 | — | — | US | claimed |
| EP-1032377-A1 | SUBSTITUTED 2-AMINOACETAMIDES AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2000-09-06 | — | — | EP | claimed |
| US-20130303568-A1 | Substituted 2-Aminoacetamides and the Use Thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2013-11-14 | — | — | US | disclosed |
| US-8426431-B2 | Substituted 2-aminoacetamides and the use thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2201945-B1 | Use of substituted 2-aminoacetamides for treating or ameliorating anxiety | PURDUE NEUROSCIENCE COMPANY (US) | 2013-03-06 | — | — | EP | disclosed |
| EP-2201944-B1 | Use of substituted 2-aminoacetamides for treating, preventing or ameliorating manic depression | PURDUE NEUROSCIENCE COMPANY (US) | 2012-05-23 | — | — | EP | disclosed |
| WO-2000061188-A9 | SODIUM CHANNEL BLOCKER COMPOSITIONS AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2002-02-14 | — | — | WO | disclosed |
| US-20020016464-A1 | Substituted 2-aminoacetamides and the use thereof | EURO-CELTIQUE S.A. | 2002-02-07 | — | — | US | disclosed |
| EP-1169060-A1 | SODIUM CHANNEL BLOCKER COMPOSITIONS AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2002-01-09 | — | — | EP | disclosed |
| WO-2000061188-A1 | SODIUM CHANNEL BLOCKER COMPOSITIONS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303568-A1 | Substituted 2-Aminoacetamides and the Use Thereof | SLC1A2, GAP43, SCN2A | SCN9A 80/4885FPR2 1231/4885CARM1 3893/4885 |
| US-20020016464-A1 | Substituted 2-aminoacetamides and the use thereof | SLC1A2, SLC1A1, SCN2A | SCN9A 90/4885FPR2 1537/4885CARM1 3653/4885 |
| US-20030130295-A1 | Substituted 2-aminoacetamides and the use thereof | SLC1A2, GAP43, SCN2A | SCN9A 57/4885FPR2 930/4885CARM1 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.